In the Canagliflozin Treatment and Trial Analysis-Sulfonylurea (CANTATA-SU) trial that enrolled patients with early-stage diabetic kidney disease, the SGLT-2 inhibitor therapy with canagliflozin was effective in reducing the plasma levels of inflammatory biomarkers, such as interleukin-6, matrix metalloproteinase-7, and tumor necrosis factor (TNF) receptor-1 [20]. Here, SLC5A2 is linked to diabetic kidney disease.